Semaglutide ingangove inonyanya kushanda GLP-1 agonist.
Parizvino, iwo akajairwa uremu-kurasikirwa zvinodhaka pamusika zvinosanganisira orlistat kubva kuRoche, liraglutide kubva kuNovo Nordisk uye semaglutide.
Wegovy, GLP-1 analogue yeNovo Nordisk, yakabvumidzwa neFDA muna 2017 kurapa chirwere cheshuga cherudzi rwechipiri.Muna Chikumi 2021, iyo FDA yakabvumidza iyo slimming chiratidzo cheWegovy.
Muna 2022, gore rekutanga rekutengesa rakazara mushure mekunyorwa kweWegovy, Wegovy yakawana madhora mazana masere nemakumi manomwe nenomwe muzviratidzo zvekurasikirwa nehuremu.
Nekunyorwa kwe semaglutide, iyo subcutaneous administration kamwe pavhiki yakavandudza zvikuru kutevedza kwevarwere, uye kushaya uremu kunooneka.Kurasikirwa kwehuremu mumavhiki e68 ndeye 12.5% yakakwirira kudarika iyo mu placebo (14.9% vs 2.4%), uye yakava chigadzirwa chenyeredzi mumusika wekurasikirwa kwehuremu kwenguva.
Muchikamu chekutanga cha2023, Wegovy akawana mari inosvika mazana matanhatu nemakumi manomwe neshanu emadhora ekuAmerica, kusvika 225% gore negore.
Kubvumirwa kwekuremera-kurasikirwa kwechiratidzo che semaglutide kunonyanya kubva pachikamu chechitatu chekudzidza chinonzi STEP.STEP yekudzidza inonyanya kuongorora maitiro ekurapa kwe subcutaneous injection ye semaglutide 2.4mg kamwe chete pavhiki kana ichienzaniswa ne placebo kune varwere vakaoma.
Chidzidzo che STEP chaisanganisira miyedzo yakawanda, umo vanenge 4,500 vakaremerwa kana kuti vakafutisa varwere vakuru vakanyoreswa, kusanganisira:
STEP 1 yekudzidza (kubatsirwa kwemararamiro ekupindira) yakaenzanisa kuchengetedzwa kwevhiki ye68 uye kushanda kwejekiseni ye subcutaneous ye semaglutide 2.4mg kamwe chete pavhiki ne placebo mu 1961 yakanyanyisa kana vanhu vakuru vanorema.
Zvigumisiro zvakaratidza kuti chiyero chekuchinja kwehuremu hwemuviri chaiva 14.9% muboka re semaglutide uye 2.4% muboka rePBO.Kuenzaniswa nePBO, iyo gastrointestinal side effects ye semaglutide inowanzoonekwa, asi yakawanda yacho inopera uye inogona kuderera pasina kumisa zvachose chirongwa chekurapa kana kuita kuti varwere vabve pakudzidza.STEP1 tsvagiridzo inoratidza kuti semaglutide ine yakanaka uremu mhedzisiro kune vakafuta varwere.
STEP 2 yekudzidza (varwere vakaoma vane chirwere cheshuga mellitus) vakaenzanisa kuchengetedzwa uye kubudirira kwejekiseni ye subcutaneous ye semaglutide 2.4 mg kamwe chete pavhiki ne placebo uye semaglutide 1.0mg mu 1210 obese kana vanhu vakuru vanorema kwevhiki dze68.
Zvigumisiro zvakaratidza kuti chiyero chehuremu hwehutatu hwemapoka matatu ekurapa chakachinja zvikuru, ne -9.6% pakushandisa 2.4 mg semaglutide, -7% pakushandisa 1.0mg ye semaglutide, uye -3.4% pakushandisa PBO.STEP2 tsvagiridzo inoratidza kuti semaglutide inoratidzawo kunaka kurasikirwa uremu mhedzisiro yevarwere vakafuta vane Type 2 chirwere cheshuga.
STEP 3 yekudzidza (adjuvant intensive behavioral therapy) yakaenzanisa kusiyana kwe68-vhiki mukuchengeteka uye kushanda pakati peinjection subcutaneous ye semaglutide 2.4 mg kamwe chete pavhiki uye placebo pamwe chete neine intensive behavioral therapy mu 611 yakanyanyisa kana yakawandisa vanhu vakuru.
Mumavhiki ekutanga e8 ekudzidza, zvidzidzo zvose zvakagamuchira yakaderera-calorie kudya kunotsiva kudya uye yakanyanyisa maitiro ekurapa mukati mepurogiramu ye68-vhiki.Vatori vechikamu vanosungirwawo kuita maminetsi e100 ekurovedza muviri svondo rega rega, nekuwedzera kwemaminetsi makumi maviri neshanu mavhiki mana ega ega uye anopfuura maminetsi mazana maviri pasvondo.
Zvigumisiro zvakaratidza kuti uremu hwemuviri wevarwere vanobatwa ne semaglutide uye intensive behavior therapy yakaderera ne16% kana ichienzaniswa nekutanga, asi iyo yeboka re placebo yakaderera ne5.7%.Kubva pane data ye STEP3, tinogona kuona mhedzisiro yekurovedza muviri uye kudya pakurasikirwa uremu, asi zvinonakidza, kusimbisa mararamiro anoita seasina mhedzisiro yekusimbisa zvinodhaka mhedzisiro ye semaglutide.
(Kuenzanisa kwehuremu hwekurasikirwa pakati peboka reSemaglutide neboka reDulaglutide)
Mushonga unogona kuwedzera glucose metabolism nekukurudzira pancreatic β masero kuti abudise insulin;Uye inhibit pancreatic alpha masero kubva pakuvhara glucagon, nokudaro kuderedza kutsanya uye postprandial shuga yeropa.
(Kuenzanisa kwehuremu hwemuviri pakati peSemaglutide boka rekurapa uye placebo)
Inofananidzwa ne placebo, Semaglutide inogona kuderedza dambudziko rekupedzisira kwezvikamu zvekupedzisira (yekutanga yemwoyo yemwoyo rufu, nonfatal myocardial infarction, nonfatal stroke) ne26%.Mushure memakore maviri ekurapa, Semaglutide inogona kuderedza zvakanyanya njodzi yekusauraya sitiroko ne39%, isina-inouraya myocardial infarction ne26% uye yemoyo kufa ne2%.Mukuwedzera, inogonawo kuderedza kudya kwekudya nekuderedza kudya uye kuderedza kudyiwa kwemudumbu, uye pakupedzisira kuderedza mafuta emuviri, izvo zvinoita kuti uremu huremerwe.
Muchidzidzo ichi, zvakaonekwa kuti phentermine-topiramate uye GLP-1 receptor agonist yakaratidza kuti ndiyo yakanyanya kunaka-kurasikirwa nemishonga pakati pevakuru vakafuta uye vakafutisa.
